This book investigates the commercialization of genetic data and the economic structures governing the modern biotechnology industry. Henry Calvin examines the intersection of genomic research and market forces, focusing on how private firms capitalize on biological information. The text provides a framework for understanding the regulatory, ethical, and financial challenges inherent in the DNA business model.

Experts identify this work as a comprehensive overview of the commercial landscape within the biotech sector. Readers frequently note the objective tone and the clear synthesis of complex economic data regarding genetic intellectual property.